AS
Therapeutic Areas
AstraZeneca Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Datopotamab deruxtecan | Non-small cell lung cancer (NSCLC) | Phase III |
| Volrustomig | 1L Non-small cell lung cancer | Phase III |
| Camizestrant | ER+ Breast Cancer | Phase III |
| Baxdrostat | Resistant Hypertension | Phase III |
| Acoramidis | ATTR Cardiomyopathy | Regulatory Review |
| Tozorakimab | COPD | Phase III |
| Eplontersen | ATTR Polyneuropathy | Phase III / Marketed |
| AZD7789 | Advanced Solid Tumors | Phase I/II |
Leadership Team at AstraZeneca
PS
Pascal Soriot
Executive Director and Chief Executive Officer
SM
Sir Mene Pangalos
Executive Vice President, BioPharmaceuticals R&D
SG
Susan Galbraith
Executive Vice President, Oncology R&D
BD
Brigitte de Lima
Senior Vice President, Chief Data & AI Officer